2/11/2009

Scintimammography developer Dilon Technologies announced a 35% increase in sales for the fourth quarter, owing to the growing public awareness and acceptance of molecular breast imaging across the U.S. More than 50,000 patients underwent Breast-Specific Gamma Imaging in 2008, said Dilon President and CEO Bob Moussa.

Related Summaries